Background REGEN-COV is a combination of 2 monoclonal antibodies (casirivimab and
imdevimab) that bind to two different sites on the receptor binding domain of the SARS-CoV …

Background Casirivimab and imdevimab are non-competing monoclonal antibodies that
bind to two different sites on the receptor binding domain of the SARS-CoV-2 spike …

Background: Casirivimab and imdevimab are non-competing monoclonal antibodies that
bind to two different sites on the receptor binding domain of the SARS-CoV-2 spike …

Casirivimab-imdevimab treatment is associated with reduced rates of mortality and
hospitalization in patients with COVID-19: A systematic review with meta-analysis - PMC Back …

Background Individuals who are immunocompromised (IC) are at high risk for severe
coronavirus disease 2019 (COVID-19). Methods Post hoc analyses of a double-blind trial …

Background The advantages and disadvantages of casirivimab-imdevimab for coronavirus
disease 2019 are not well understood. We conducted a systematic review and meta …

Introduction Casirivimab and imdevimab (CAS/IMV) are two non-competing, high-affinity
human IgG1 anti-SARS-CoV-2 monoclonal antibodies, that showed a survival benefit in …

Abstract Background Corona Virus disease-2019 (COVID-19) disease induces scientific
research to find a control to this pandemic from 2020 year up to now. Recently, various …

Background: Tixagevimab/cilgavimab is a neutralising monoclonal antibody combination
hypothesized to improve outcomes for hospitalised COVID-19 patients. Methods: In a phase …

Aim: This study aimed to report clinical courses of patients who had mild coronavirus
disease 2019 (COVID-19), defined as SpO2 of 96 or higher, and treated with/without …